DOSAGE AND ADMINISTRATION Important:
Colistimethate for injection is supplied in vials containing colistimethate
sodium equivalent to 150 mg colistin base activity per vial.
The 150 mg vial should be reconstituted with 2.0 mL Sterile Water for Injection,
USP. The reconstituted solution provides colistimethate sodium at a
concentration equivalent to 75 mg/mL colistin base activity.
During reconstitution swirl gently to avoid frothing.
Parenteral drug products should be inspected visually for particulate matter and
discoloration prior to administration, whenever solution and container permit.
If these conditions are observed, the product should not be used.
Adults and pediatric patients – Intravenous or Intramuscular Administration:
Colistimethate for injection should be given in 2 to 4 divided doses at dose
levels of 2.5 to 5 mg/kg per day for patients with normal renal function,
depending on the severity of the infection.
In obese individuals, dosage should be based on ideal body weight.
The daily dose should be reduced in the presence of renal impairment.
Modifications of dosage in the presence of renal impairment are
presented in Table 1 below:
TABLE 1. Suggested Modification of Dosage
Schedules of Colistimethate for Injection for Adults with Impaired Renal
suggested unit dose is 2.5 to 5 mg/kg; however, the time INTERVAL
between injections should be increased in the presence of impaired
Degree of Impairment
Plasma creatinine, mg/100 mL
Urea clearance, % of normal
Unit dose of Colistimethate
for injection , mg
4 to 2
2 or 1
every 36 hr
Total daily dose, mg
Approximate daily dose, mg/kg/day
2.5 - 5 mg/kg/day in 2 to 4
2.5 - 3.8 mg/kg/day in 2
1.6 - 2.5 mg/kg/day in 1 to 2
~1.5 mg/kg q36 hours
See package insert.
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read